How to Select a Local Agent for Medical Device Overseas Registration

How to Select a Local Agent for Medical Device Overseas Registration?

Selecting a local agent is a critical step in overseas registration for medical devices. Companies should first assess whether the agent holds the necessary regulatory qualifications in the target country and can issue authorisation letters, signed documents, and registration applications in the required local format. The agent must be familiar with the registration pathway corresponding to the product’s risk classification (e.g., GHWP member states, ASEAN, Middle East) and capable of guiding the manufacturer to prepare or convert technical documentation—including performance verification, risk management reports, clinical evaluation summaries—quality management system evidence (ISO 13485 certificate, MDSAP report), and localised labels and instructions for use. The agent must assume post-market maintenance obligations, including adverse event reporting, change notifications, and renewal applications. Common risks include the agent lacking local regulatory competence, unclear division of responsibilities between agent and manufacturer, and the agent being unable to support coordinated registrations across multiple countries. Companies should request the agent to provide past successful cases, qualification proofs, a list of service scope, and clearly define document control rights, change processes, and renewal guarantees in the contract. In the early stages, priority should be given to agents who have already completed registration of similar products in the target country, and their communication channels with regulatory authorities should be verified.

Key Considerations for Chinese Medical Device Companies

For Chinese medical device companies, a prudent approach is to first conduct product classification and documentation gap analysis, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Registration in the target market typically affects technical documentation, authorised representative arrangements, importer coordination, label language, quality system evidence, and subsequent change maintenance. If the company proceeds merely by submitting a list of required documents without addressing these dimensions, it may face supplementary requests or rework regarding model coverage, consistency of evidence chains, label claims, and certificate control rights.

AIMEILI recommends that companies integrate this issue into a unified GHWP member state and multi-country access strategy, using a set of reusable core technical documents to support localisation across different markets rather than re-creating documents from scratch for each country.

Applicable Scenarios and Core Issues

Companies searching for "How to select a local agent for medical device overseas registration" are typically not seeking a conceptual explanation but rather want to determine whether existing documentation can support target market submissions, whether a local agent or authorised representative is needed, why timelines are extended, and which issues could impact their market launch. This question often simultaneously involves product classification, registration pathways, evidence chains, label localisation, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states, Southeast Asia, the Middle East, or Latin America simultaneously, addressing only one country’s process is insufficient. A more valuable approach is to first develop reusable versions of core technical documents, quality system evidence, performance verification, clinical evidence, and labels/instructions for use, then localise them according to each country’s regulatory requirements.

Registration Decision Logic

Before selecting a local agent, the manufacturer must complete an internal assessment: Does the product fall within the definition of a medical device in the target country? What is the product’s risk classification? What is the corresponding registration pathway (simple notification, registration, or pre-market approval)?

Step 1: Confirm product classification. Different countries have different classification criteria, e.g., EU MDR classification, ASEAN technical classification, Saudi Arabia’s GHTF-based classification. The agent should be able to provide classification support.

Step 2: Evaluate whether the existing QMS can be reused. ISO 13487 certificate and MDSAP report are accepted by most countries. If the company already has CE or FDA market approvals, relevant technical documents can be partially converted.

Step 3: Determine the statutory functions of the local agent. The agent must assume responsibilities including: submitting registration applications, direct communication with regulatory authorities, receiving adverse event reports, assisting with onsite inspections, and handling changes and renewals.

Step 4: Analyse synergy for multi-country registrations. If the company plans to register in multiple GHWP member states simultaneously, priority should be given to agencies that can provide services for multiple countries to avoid duplicate coordination.

Documentation and Evidence

Documents to be prepared and provided to the agent include: manufacturer’s business license, medical device registration certificate (if any), product description, instructions for use, technical document summary (design principle, materials, process), performance verification reports, electrical safety and biocompatibility test reports, risk management report (ISO 14971), stability data, clinical evaluation or clinical trial summary, label samples, QMS certificate, and declaration of conformity.

Evidence the agent should provide: agency agreement or letter of authorisation, local business license or registration certificate, list of past successful registration cases, historical communication records with regulatory authorities (if any), service fee schedule, and contract terms.

For GHWP member states, the agent must have the ability to translate English documents into the local language and adjust document formats to meet local technical review requirements.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating NMPA documents from China without restructuring evidence according to the target market pathway.
• Overly broad model range with insufficient test reports, clinical evidence, or label coverage.
• Selecting a local agent solely based on sales cooperation without clearly defining regulatory responsibilities, certificate control rights, and post-market maintenance obligations.
• Inconsistencies between labels, instructions for use, promotional materials, and registration documentation, leading to supplementary requests or post-market compliance risks.
• Failure to plan for multi-country document reuse, resulting in repeated document preparation for each country, increasing both cost and timeline.

Company Preparation Checklist

• Define target countries and their corresponding medical device regulatory frameworks.
• Complete product risk classification and confirm the registration pathway.
• Organise existing QMS evidence (ISO 13485, MDSAP, etc.).
• Prepare complete technical documentation and assess gaps relative to target country requirements.
• Develop a content plan for localised labels and instructions for use.
• Search for 3-5 candidate agents, requesting qualification proofs and case studies.
• Communicate with the agent to confirm service scope, fees, and contract terms.
• Clearly define document ownership, confidentiality, change processes, and renewal obligations in the agency agreement.
• Establish an internal post-market surveillance process to coordinate adverse events and changes with the agent.
• When considering multi-country registrations, evaluate whether the agent can provide one-stop services or coordinate multiple agents.

AIMEILI Perspective

The most common misjudgment by companies is believing the agent can handle everything, thereby relaxing control over technical document localisation. In reality, the agent’s core role is a bridge, not a substitute for the manufacturer’s technical subject matter. The most important step before signing an agent is to complete an internal regulatory gap analysis of the product, clarifying which documents can be reused and which must be localised. For example, a clinical evaluation report may only need format adjustment, but labels and instructions for use must be redrafted according to local language and symbol requirements. Certificate control rights with the local agent are easily overlooked: if the agent changes or terminates the cooperation, the manufacturer may lose continued possession of the registration certificate.

Therefore, the contract must stipulate the agent’s obligation to cooperate with the manufacturer in transferring the agent or renewing the certificate after the product is successfully registered. For multi-country registrations, the core part of the technical documents should be unified as much as possible, with targeted supplements only for differences in each country’s requirements. The agent should help identify these differences to avoid duplicate work and supplementary requests. AIMEILI recommends using a "core document package + country-specific variation package" approach, which improves efficiency and reduces communication costs with the agent.

Frequently Asked Questions

How to verify an agent’s regulatory qualifications?

Request the agent to provide any local regulatory authority-issued agency service license (if applicable), social insurance registration, or industry association membership certificates. Review their list of past successful registrations, preferably for products similar in type or risk classification. Contact the target country’s regulatory authority by email to verify if the agent appears on its list of registered agents (e.g., the Saudi SFDA’s authorised representative registration list).

How are agent fees typically structured?

Fees usually include initial registration application fee, technical document review fee, local language translation and format conversion fee, regulatory communication service fee, and annual maintenance fee (covering adverse event monitoring, change notifications, renewal procedures). The fee structure should be clearly stated in the contract to avoid hidden charges.

What should the manufacturer do if the agent withdraws or goes bankrupt?

The contract should stipulate in advance that the agent is obligated to provide at least 90 days’ notice and assist the manufacturer in replacing the agent. The manufacturer should retain copies of all original technical documents and have the right to apply directly to the regulatory authority for a change of agent. It is advisable to identify, at the start of registration, the regulatory authority’s process for accepting a manufacturer’s application to change the agent.

Quality System and Evidence Consistency

From the perspective of regulatory review, quality system documentation is not an isolated certificate. Regulators typically examine consistency between manufacturer name, production address, product scope, certificate validity period, applicable standards, and technical documents. If the scope of the ISO 13485 certificate does not match the product under application, or if production addresses, model specifications, or instruction manual versions are inconsistent with test reports, the company may be asked to provide supplementary explanations even if extensive documents have been prepared.

Before submission, companies should create an evidence consistency checklist that aligns product name, model/specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and QMS certificate. This basic step significantly reduces the likelihood of supplementary requests, especially for projects involving multiple GHWP member states or multiple product series.

Localisation Conversion and Agent Responsibilities

Target market registration projects often involve arrangements for local agents, authorised representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and market stability.

Labels, instructions for use, and authorisation documents cannot simply be translated. Companies should check local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information, and after-sales contact details. For companies with existing CE, FDA, NMPA, or other market documentation, the focus of localisation conversion should be on transforming reusable evidence into a submission structure acceptable to the target country, rather than creating an entirely new set of documents.

Post-Market Maintenance and Long-Term Planning

Obtaining registration does not mean compliance is complete. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label updates, and regulatory update records. Many companies invest heavily during the registration phase but neglect post-market maintenance, leading to disconnection between certificates and market sales when production address changes, model expansions, IFU updates, or agent changes occur.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first clarify target market priorities, then build a reusable documentation package and country-specific gap list, and finally schedule submission, supplementary response, post-market maintenance, and renewal milestones. This approach not only improves single-country registration efficiency but also enables the company to develop a replicable overseas compliance capability, reducing the cost of starting from scratch for each new market.